The Depression Therapeutics Market, estimated at USD 14.09 Bn in 2025, is expected to exhibit a CAGR of 4.5% and reach USD 19.17 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Key market players are focusing on adopting growth strategies such as signing collaboration agreements with market players, which will drive the global depression therapeutics market. For instance, in August 2025, Otsuka America Pharmaceutical, Inc. (Otsuka), a pharmaceutical company, announced that it had signed a collaboration agreement to facilitate access to the ABILIFY MYCITE System for select regional provider networks contracted through Magellan Health. The ABILIFY MYCITE System provides an opportunity for a connected care approach to treatment and tracks if ABILIFY MYCITE (aripiprazole tablet with sensor) has been taken.
Global Depression Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
The governments of various countries were taking various initiatives to combat COVID-19. For instance, in January 2025, the U.S. started a coordinated pandemic response through the publication of the National Strategy for the COVID-19 Response and Pandemic Preparedness. This not only enhanced the effectiveness of the fight against COVID-19 but also helped in restoring people’s trust, accountability, and sense of common purpose in response to the pandemic. Moreover, governments, multilateral organizations, and private companies had invested billions of dollars in developing viable COVID-19 vaccines. According to the Council on Foreign Relations, in 2025, more than thirty vaccines had received approval for routine or urgent usage in several nations. Over twelve billion COVID-19 vaccine doses had been provided across the globe by June 2025. At least three-quarters of the population has received all recommended vaccinations in various nations. The highest immunization rates are seen in Qatar, Singapore, and the U.A.E. Furthermore, according to the Government of India, on August 4, 2025, the Union Government was dedicated to stepping up and broadening the COVID-19 vaccination program nationwide. On January 16, 2025, the countrywide COVID-19 immunization campaign began. On June 21, 2025, a new phase of COVID-19 vaccination was made mandatory. The availability of more vaccinations and early notification of vaccine availability to states and union territories (UTs) for improved planning related to the COVID-19 vaccine and streamlining the vaccine supply chain have boosted the vaccination campaign.
Moreover, in the U.S., the COVID-19 vaccines were available for free to everyone of age 6 months and older living in the U.S., regardless of immigration or insurance status.
Global Depression Therapeutics Market: Key Developments
- In August 2025, Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia.
- In December 2025, Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
- In June 2025, Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced positive results from its Phase 1b clinical trial of CVL-231, a novel muscarinic M4-selective Positive Allosteric Modulator (PAM), in adult patients with schizophrenia. CVL-231 is an M4-selective PAM being developed as a potential treatment for schizophrenia. CVL-231 is designed as a once-daily medication that selectively targets activation of the M4 receptor in the brain to reduce dopaminergic activity without direct dopamine receptor antagonist activity.